Comprehensive Overview of Rare Diseases and Orphan Drugs: Prevention, Diagnosis, and Treatment

A comprehensive approach to the treatment of orphan diseases requires continuous patient support, ranging from preventive care and the early identification of at-risk groups to ensuring access to drugs for both children and adults. It would be impossible for patients to have access to rare disease therapies at each stage of their life without synchronized efforts on the part of the scientific and medical communities, drug manufacturers, and the regulatory authorities. The development of modern orphan drugs is primarily being driven by advancements in reproductive and molecular genetics, preimplantation diagnostics, neonatal screening, as well as the introduction of modern approaches to diagnosing rare diseases. The localization of drug development and manufacturing, as well as the expansion of the domestic pharmaceutical industry’s capacity, both in terms of supplying the domestic market with innovative orphan drugs and integrating Russian-made solutions into global chains, are critical prerequisites for ensuring the system’s effectiveness and safety. This also requires the smooth integration of legislative initiatives (such as expanding state guarantee programmes and mechanisms for supporting regional budgets) and the active involvement of patient communities as a driving force for legislative change. What mechanisms for synchronizing medical and regulatory decisions could help establish a continuous system of care for rare diseases? What state support measures are needed to incentivize the development and domestic manufacturing of pharmaceutical substances and drugs? How can we find a balance between accelerating the introduction of innovations and maintaining high standards of safety and efficacy? What role do patient communities and legislative initiatives play in shaping an accessible drug provision system?